scispace - formally typeset
D

Dmitry Napalkov

Researcher at I.M. Sechenov First Moscow State Medical University

Publications -  48
Citations -  105

Dmitry Napalkov is an academic researcher from I.M. Sechenov First Moscow State Medical University. The author has contributed to research in topics: Atrial fibrillation & Dabigatran. The author has an hindex of 5, co-authored 39 publications receiving 86 citations. Previous affiliations of Dmitry Napalkov include Moscow State University.

Papers
More filters
Journal ArticleDOI

Prolonged dry apnoea: effects on brain activity and physiological functions in breath-hold divers and non-divers

P.O. Ratmanova, +6 more
- 17 May 2016 - 
TL;DR: Apnoea up to 5 min does not lead to notable cerebral hypoxia or a decrease of brain performance in either breath-hold divers or non-divers, and seems to be the result of the compensatory mechanisms similar to the diving response aimed at centralising blood circulation and reducing peripheral O2 uptake.
Journal ArticleDOI

Age-related changes in saccadic eye movements in healthy subjects and patients with Parkinson’s disease

A. S. Litvinova, +5 more
- 16 Apr 2011 - 
TL;DR: According to the data obtained, the saccade characteristics depend on the age in both the subjects without neurological symptoms and parkinsonian patients, and the percentage of multistep saccades in patients with Parkinson’s disease significantly exceeds the values in healthy subjects from the age-matched groups.
Journal ArticleDOI

Anticoagulant therapy in everyday clinical practice: data of the retrospective cross-sectional study

V. A. Sulimov, +4 more
- 21 Sep 2015 - 
TL;DR: More than a third of non-valvular AF patients receive inadequate antithrombotic therapy in routine clinical practice, and low incidence rate of the novel oral anticoagulants prescription despite the advantages of such treatment also calls attention.
Journal ArticleDOI

Comparative efficacy and safety of new oral anticoagulants

V. A. Sulimov, +2 more
- 01 Jan 2013 - 
TL;DR: Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed indirect comparisons.
Journal ArticleDOI

[Natriuretic Peptides: Role in Current Cardiology].

Burnasheva Ga, +1 more
- 03 Dec 2015 - 
TL;DR: It was demonstrated that monitoring the level of NT-proBNP can be used for the selection of optimal therapy, affect the course and outcome of the disease, and reduce the cost of treatment.